News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ohr Pharma (OHRP) To Announce Fiscal Third Quarter 2017 Results On August 8



7/31/2017 1:10:39 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it will report financial results for its third fiscal quarter ended June 30, 2017 after the market close on Tuesday, August 8, 2017. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.

Conference Call & Webcast
Tuesday, August 8th @ 5pm Eastern Time
Domestic: 877-407-0789
International: 201-689-8562
Conference ID: 13665443
Webcast: http://public.viavid.com/index.php?id=125142
Replays – Available through August 15, 2017
Domestic: 844-512-2921
International: 412-317-6671
Conference ID: 13665443

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.

Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 ir@ohrpharmaceutical.com LifeSci Advisors, LLC Michael Wood 646-597-6983 mwood@lifesciadvisors.com

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES